ARS Pharmaceuticals (SPRY) Other Accumulated Expenses (2024 - 2026)

ARS Pharmaceuticals has reported Other Accumulated Expenses for 3 years, with the latest figure at $592000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $592000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $592000.0 (changed N/A YoY) and the FY2025 annual result came in at $588000.0, up 1300.0% from the prior year.
• Other Accumulated Expenses improved to $592000.0 in Q1 2026 per SPRY's latest filing, from $588000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $3.1 million in Q3 2025 and troughed at $42000.0 in Q4 2024.
• A 3-year average of $1.1 million and a median of $590000.0 in 2025 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 1300.0% in 2025, down 1300.0% in 2025.
• Over 3 years, Other Accumulated Expenses stood at $42000.0 in 2024, then surged by 1300.0% to $588000.0 in 2025, then rose by 0.68% to $592000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $592000.0, $588000.0, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.